Ophthalmic medical technology company commercializing adjustable intraocular lenses and light delivery systems for cataract surgery.
Profile & Fundamentals
RxSight: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
RxSight Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Company profile record
Rxsight Inc
Common Stock · Health Care · Health Care Supplies
Company
- Company / asset
- Rxsight Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Health Care Supplies
- HQ
- 🇺🇸 United States
- Head office
- 100 Columbia, Aliso Viejo, CA, United States, 92656
Leadership & scale
- Chief executive
- Mr. Aziz Mottiwala M.B.A.
- CEO year born
- 1978
- Full-time employees
- 461
- Fiscal year end
- December
- IPO date
- 2021-07-30
Fundamentals snapshot
- Market Cap
- USD 192.9M
- P/E
- --
- Revenue (Q2 26)
- USD 33.7M
- Profit (Q2 26)
- USD -12.1M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 134.5M
- Shares in public float
- 33.7M
- Insider ownership
- 6.57%
Reporting & identifiers
- Symbol
- RXST.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US78349D1072
- Asset ID
- equity_73ac566d-3909-558b-b1ed-6b4754a19ed8
Ownership
Shares Outstanding
Latest: 41.5M | Max: 41.5M | Min: 19.1M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
81.24%
33.7M latest reported shares
Insider Ownership
6.57%
Latest reported insider stake
Short Float
0.10%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2020-01-01 | 19,073,100 |
| 2021-01-01 | 27,352,600 |
| 2022-01-01 | 27,990,300 |
| 2023-01-01 | 35,961,900 |
| 2024-01-01 | 40,356,800 |
| 2025-01-01 | 41,175,700 |
| 2026-01-01 | 41,490,900 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 3,187,092 | 7.66% | 2026-03-31 |
| Millennium Management LLC | 3,030,287 | 7.29% | 2026-06-30 |
| No Street GP LP | 2,055,000 | 4.94% | 2026-06-30 |
| Nomura Holdings Inc | 2,000,060 | 4.81% | 2026-06-30 |
| D. E. Shaw & Co LP | 1,985,215 | 4.77% | 2026-06-30 |
| Vanguard Capital Management, LLC | 1,692,935 | 4.07% | 2026-03-31 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1,227,155 | 2.95% | 2026-08-31 |
| Bank of America Corp | 1,210,039 | 2.91% | 2026-03-31 |
| Federated Hermes Inc | 1,201,195 | 2.89% | 2026-06-30 |
| Two Sigma Investments LLC | 1,147,048 | 2.76% | 2026-06-30 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1,131,400 | 2.72% | 2026-03-31 |
| Jacobs Levy Equity Management, Inc. | 1,066,321 | 2.56% | 2026-03-31 |
| BlackRock Advantage Small Cap Core Instl | 1,031,448 | 2.48% | 2026-08-31 |
| Acadian Asset Management LLC | 1,019,127 | 2.45% | 2026-03-31 |
| iShares Russell 2000 ETF | 1,012,959 | 2.44% | 2026-08-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Headline financial results show a business navigating a major commercial pivot. Trailing revenue contracted to one hundred twenty-eight million dollars as clinic console purchases fell forty-eight percent in fiscal 2025. However, underlying consumable lens procedure volume grew twelve percent, providing a stable foundation beneath hardware volatility. Second-quarter 2026 revenue stabilized at thirty-three million seven hundred thousand dollars, aided by initial partnership licensing payments. This transition conceals improving underlying business quality behind headline accounting losses. Operating losses reached fifty-five million dollars over the trailing twelve months due to commercial expansion and legal costs. However, cash burn runs at roughly half that level because stock compensation is non-cash, and recurring lens sales are gradually replacing hardware as the primary revenue engine.
Headline financial results show a business navigating a major commercial pivot. Trailing revenue contracted to one hundred twenty-eight million dollars as clinic console purchases fell forty-eight percent in fiscal 2025. However, underlying consumable lens procedure volume grew twelve percent, providing a stable foundation beneath hardware volatility. Second-quarter 2026 revenue stabilized at thirty-three million seven hundred thousand dollars, aided by initial partnership licensing payments. This transition conceals improving underlying business quality behind headline accounting losses. Operating losses reached fifty-five million dollars over the trailing twelve months due to commercial expansion and legal costs. However, cash burn runs at roughly half that level because stock compensation is non-cash, and recurring lens sales are gradually replacing hardware as the primary revenue engine.
Revenue, Net Income, and Free Cash Flow
Latest: USD 134.5M | Max: USD 139.9M | Min: USD -66.8M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: --
No history available.
Profitability & Margins
Margins and Operating Efficiency
AI Review
Gross profit margins tell a remarkable story of structural improvement beneath headline operating deficits. Corporate gross margins surged from seventy point seven percent in 2024 to seventy-six point six percent in 2025, reaching seventy-six point seven percent in mid-2026. This expansion reflects an advantageous mix shift toward proprietary consumable lenses, which deliver significantly higher profitability than capital delivery consoles. Operating margins remain temporarily depressed at negative thirty-five point eight percent due to dedicated commercial sales infrastructure. However, product unit economics remain robust. As high-margin recurring lens procedures expand across the installed machine base and licensing income flows through with minimal added costs, operating leverage will steadily convert gross profits into sustainable operating earnings.
Gross profit margins tell a remarkable story of structural improvement beneath headline operating deficits. Corporate gross margins surged from seventy point seven percent in 2024 to seventy-six point six percent in 2025, reaching seventy-six point seven percent in mid-2026. This expansion reflects an advantageous mix shift toward proprietary consumable lenses, which deliver significantly higher profitability than capital delivery consoles. Operating margins remain temporarily depressed at negative thirty-five point eight percent due to dedicated commercial sales infrastructure. However, product unit economics remain robust. As high-margin recurring lens procedures expand across the installed machine base and licensing income flows through with minimal added costs, operating leverage will steadily convert gross profits into sustainable operating earnings.
Profitability Margins
Latest: 76.6% | Max: >100.0% | Min: <-100.0%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
76.6%
Gross profit / revenue
Operating Margin
-35.8%
Operating income / revenue
Net Margin
-29.0%
Net income / revenue
FCF Margin
-14.4%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2019-12-31 | 2,241,000 | 126,220,000 | -44,705,000 |
| 2020-12-31 | 14,678,000 | 27,575,000 | -37,742,000 |
| 2021-12-31 | 22,593,000 | -48,688,000 | -46,648,000 |
| 2022-12-31 | 49,005,000 | -66,756,000 | -61,243,000 |
| 2023-12-31 | 89,077,000 | -48,608,000 | -46,407,000 |
| 2024-12-31 | 139,927,000 | -27,455,000 | -22,386,000 |
| 2025-12-31 | 134,477,000 | -38,943,000 | -19,341,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
No reported records are available in this preview.
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2019-12-31 | -81.17 | -2,055.78 | 5,632.31 | -1,994.87 |
| 2020-12-31 | 11.62 | -241.21 | 187.87 | -257.13 |
| 2021-12-31 | 19.99 | -233.64 | -215.5 | -206.47 |
| 2022-12-31 | 43.52 | -129.21 | -136.22 | -124.97 |
| 2023-12-31 | 60.36 | -56.23 | -54.57 | -52.1 |
| 2024-12-31 | 70.71 | -26.34 | -19.62 | -16 |
| 2025-12-31 | 76.6 | -35.84 | -28.96 | -14.38 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.